CD274 and head and neck squamous cell carcinoma: In HNSCC, current guidelines established ICIs as a standard of care first-line treatment in PD-L1 positive patients in recurrent/metastatic settings based on the KEYNOTE-040 and 048 trials [6,7], either combined with chemotherapy or in monotherapy.